Results 101 to 110 of about 2,820 (114)

AB0269 Importance of steady-state trough concentrations after intravenous golimumab with concomitant methotrexate in patients with active rheumatoid arthritis

Annals of the Rheumatic Diseases, 2013
Objectives To determine an optimized dosing regimen for IV golimumab in patients with active RA using population pharmacokinetic (PK) modeling and simulation. Methods Two Phase 3 trials were performed for IV golimumab. In the first trial, IV infusions of 2 mg/kg golimumab every 12 weeks (Q12W) or 4 mg/kg Q12W with concomitant methotrexate (MTX) were
J.H. Leu, Z. Xu, C. Hu, A. Mendelsohn, J. Ford, H.M. Davis, H. Zhou   +6 more
openaire   +1 more source

The Effect of Intravenous Golimumab on Health-related Quality of Life in Rheumatoid Arthritis: 24-week Results of the Phase III GO-FURTHER Trial

The Journal of Rheumatology, 2014
Objective.To evaluate the effects of intravenous (IV) golimumab 2 mg/kg + methotrexate (MTX) on patient-reported measures of health-related quality of life (HRQOL) in patients with active rheumatoid arthritis (RA) despite prior MTX therapy.Methods.In this randomized, multicenter, double-blind, placebo-controlled, phase III trial, adults with RA were ...
Clifton O, Bingham, Michael, Weinblatt, Chenglong, Han, Timothy A, Gathany, Lilianne, Kim, Kim Hung, Lo, Dan, Baker, Alan, Mendelsohn, Rene, Westhovens   +8 more
openaire   +2 more sources

Incidence of infusion reactions to intravenous golimumab: results from a prospective, real-world community registry

Clinical and Experimental Rheumatology, 2020
Rafat, Faraawi, Andrew, Chow, Majed, Khraishi, Derek, Haaland, François, Nantel, Brendan, Osborne   +5 more
openaire   +2 more sources

Golimumab intravenous infusion for the treatment of rheumatoid arthritis

The Nurse Practitioner, 2015
openaire   +1 more source

Population Pharmacokinetic and Exposure–Response Model Simulations: Predicted Exposure and Efficacy for Maintenance Doses of Intravenous Golimumab Every 6 or 8 Weeks in Patients With Moderately to Severely Active Rheumatoid Arthritis

Clinical Therapeutics, 2022
Aaron Broadwell, Chuanpu Hu, Omoniyi J Adedokun   +2 more
exaly  

The effect of intravenous golimumab on health-related quality of life and work productivity in adult patients with active ankylosing spondylitis: results of the phase 3 GO-ALIVE trial

Clinical Rheumatology, 2020
John D Reveille, Mark C Hwang, Abhijeet Danve   +2 more
exaly  

0341 Outcome metrics of intravenous golimumab for hidradenitis suppurativa

Journal of Investigative Dermatology
H. Tai, A. Parvathaneni, K. Hill, Z. Islam, E. Axler, S. Cohen   +5 more
openaire   +1 more source

Propensity score matching/reweighting analysis comparing intravenous golimumab to infliximab for ankylosing spondylitis using data from the GO-ALIVE and ASSERT trials

Clinical Rheumatology, 2020
L S Gensler, S D Chakravarty, Chris Cameron   +2 more
exaly  

Pharmacokinetics and Safety of Golimumab, a Fully Human Anti-TNF-α Monoclonal Antibody, in Subjects With Rheumatoid Arthritis

Journal of Clinical Pharmacology, 2007
Roy Fleischmann, Zhenhua Xu, Qun Jiao
exaly  

Golimumab in the treatment of psoriatic arthritis

Expert Review of Clinical Immunology, 2018
Thorvardur Jon Love, Arthur Kavanaugh
exaly